The over-the-counter rule is not a strength chart
FDA says hydroquinone skin-lightening products are not approved for over-the-counter sale in the United States. A claim that a low percentage is simply a mild cosmetic option does not resolve that issue. An online marketplace's willingness to list or ship a product is not evidence of an appropriate regulatory pathway.
FDA also warns that some illegal skin-lightening products may omit concerning ingredients from their labels. A familiar-looking jar or a reassuring product name therefore cannot replace checking who supplies the product and how it is being prescribed. A review should not direct readers to bypass assessment through an unlabeled or ambiguously labeled import.
This does not mean all prescription hydroquinone use has been prohibited. FDA's consumer information distinguishes prescription access from over-the-counter sale. The practical question is which exact preparation is being offered, under what prescribing arrangement and by which dispensing pharmacy.
Approval belongs to a particular product
Tri-Luma is an example of a specifically approved prescription combination. Its label identifies fluocinolone acetonide, hydroquinone and tretinoin, with a defined indication involving short-term treatment of moderate to severe facial melasma alongside sun-avoidance measures. The label also contains limitations that matter to interpretation.
The existence of that product does not establish that every cream containing hydroquinone is FDA-approved. Nor does it make a preparation with similar ingredient names an interchangeable copy. Concentrations, the identity of a corticosteroid, inactive ingredients, manufacturing and the product's approval record can all differ.
A legitimate question for the prescriber or pharmacist is: “What is the exact name and regulatory status of the preparation I would receive?” If it is a commercially manufactured medicine, ask for its current label. If it is compounded, ask for the formulation and pharmacy information. The answer should describe the actual order, not a general statement that the ingredients are familiar.
Compounding serves a different role
FDA explains that compounded drugs can meet particular medical needs, while also emphasizing that they are not FDA-approved finished products. The agency does not review each compounded preparation's safety, effectiveness and quality before marketing in the same way it reviews an approved medicine.
That is a category distinction, not a finding by this publication that a named compounded cream is defective. We have not tested provider products or inspected their production. The useful next question is why a compounded option is being considered for the individual patient and how the prescriber and pharmacist explain its benefits and limitations.
For example, CoreAge Rx's Spot On names a hydroquinone, kojic acid and niacinamide combination. Musely's Spot Cream covers several different formula options. They should be evaluated as the specific preparations proposed, rather than being given another product's approval or study findings by association.
A prescription request is not a guaranteed prescription
An online health questionnaire is part of an assessment pathway. It is not a promise that a requested ingredient, concentration or duration will be authorized. A clinician may recommend a different approach, request additional information or decide that an in-person examination is needed.
A service should explain what happens in those circumstances, including the treatment of any consultation charge. That is a commercial question worth resolving before payment. It should not become pressure on a clinician to prescribe simply because a reader chose a product page first.
Photographs also have limits. A mark can require a closer examination than a remote form permits, and a product category such as “dark spots” does not establish a diagnosis. Our guide to melasma and other pigmentation concerns explains why the name of the condition should precede the formula comparison.
Identify the dispenser, not just the website
FDA's online-pharmacy resource links to state licensing databases and describes basic checks, including a prescription requirement and access to a pharmacist. The provider's brand and the dispensing pharmacy may be different organizations. Ask which pharmacy will prepare or supply the actual order.
Keep its name, address and contact information with the prescription. If there is uncertainty about the label, ingredients, storage or the condition of a delivery, that information helps you reach the appropriate professional. A site's general customer-service chat may not be the same route as a pharmacist's medication advice.
Our reviews identify what the public pages establish and where an individual order still needs verification. They do not certify every participating pharmacy. The Skin Medicinals review, for example, discusses a policy naming several possible fulfillers without claiming that this publication audited all of them.
Keep a usable record before the first application
The record should include the diagnosis discussed with the clinician, the exact preparation, instructions, review arrangements and whom to contact with problems. Add the quantity and billing schedule to the same folder, while remembering that payment dates do not dictate treatment duration.
If a statement on the marketing page conflicts with the actual label or clinical instructions, ask for clarification instead of choosing the version that sounds more convenient. Do not resolve uncertainty by increasing an application, extending a course or substituting another product yourself.
The next step in this guide is the strengths and combinations article. It builds on the regulatory distinction with a practical way to read a formula, without turning this publication into a prescribing service.